Abstract | OBJECTIVES: METHODS: Between June 2021 and November 2021, we retrospectively evaluated blood samples from 60 healthy controls (control group), 57 patients with urothelial carcinoma, and 28 patients with renal cell carcinoma who had received two doses of the BNT162b2 vaccine at Hirosaki University Hospital. We determined the immunoglobulin G antibody titers against the severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain. Seropositivity was defined as ≥15 U/mL. We investigate factors associated with antibody titers and seropositivity in the patients with urothelial carcinoma and renal cell carcinoma. RESULTS: Antibody titers in the control, urothelial carcinoma, and renal cell carcinoma groups were 813, 431, and 500 U/mL, respectively. Seropositivity was 100%, 90%, and 96% in the control, urothelial carcinoma, and renal cell carcinoma groups, respectively. Of the 85 patients, 37 of 57 (65%) and 21 of 28 (75%) were actively undergoing anticancer treatment for urothelial carcinoma and renal cell carcinoma, respectively. Anti-severe acute respiratory syndrome coronavirus 2 spike immunoglobulin G antibody titers and seropositivity was not significantly different between the patients with urothelial carcinoma and renal cell carcinoma. Anti-severe acute respiratory syndrome coronavirus 2 spike immunoglobulin G antibody titers were not significantly associated with active anticancer therapy or steroid treatment for immune-related adverse events. Univariable logistic regression analysis revealed that older age and metastatic disease were significantly and negatively associated with seropositivity. CONCLUSIONS:
|
Authors | Kyo Togashi, Shingo Hatakeyama, Tohru Yoneyama, Tomoko Hamaya, Takuma Narita, Naoki Fujita, Hiromichi Iwamura, Teppei Okamoto, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama |
Journal | International journal of urology : official journal of the Japanese Urological Association
(Int J Urol)
Vol. 29
Issue 7
Pg. 733-739
(07 2022)
ISSN: 1442-2042 [Electronic] Australia |
PMID | 35362143
(Publication Type: Journal Article)
|
Copyright | © 2022 The Japanese Urological Association. |
Chemical References |
- Antibodies, Viral
- COVID-19 Vaccines
- Immunoglobulin G
- BNT162 Vaccine
|
Topics |
- Antibodies, Viral
- BNT162 Vaccine
- COVID-19
(prevention & control)
- COVID-19 Vaccines
- Carcinoma, Renal Cell
(drug therapy)
- Carcinoma, Transitional Cell
(drug therapy)
- Humans
- Immunoglobulin G
- Kidney Neoplasms
(drug therapy)
- Retrospective Studies
- SARS-CoV-2
- Urinary Bladder Neoplasms
(drug therapy)
|